|
|
Background Treatment of acute Kawasaki disease with intravenous immune globulin and aspirin reduces the risk of coronary-artery abnormalities and systemic inflammation, but despite intravenous immune globulin therapy, coronary-artery abnormalities develop in some children. Studies have suggested that primary corticosteroid therapy might be beneficial and that adverse events are infrequent with short-term use.
Methods We conducted a multicenter, randomized, double-blind, placebo-controlled trial to determine whether the addition of intravenous methylprednisolone to conventional primary therapy for Kawasaki disease reduces the risk of coronary-artery abnormalities. Patients with 10 or fewer days of fever were randomly assigned to receive intravenous methylprednisolone, 30 mg per kilogram of body weight (101 patients), or placebo (98 patients). All patients then received conventional therapy with intravenous immune globulin, 2 g per kilogram, as well as aspirin, 80 to 100 mg per kilogram per day until they were afebrile for 48 hours and 3 to 5 mg per kilogram per day thereafter.
Results At week 1 and week 5 after randomization, patients in the two study groups had similar coronary dimensions, expressed as z scores adjusted for body-surface area, absolute dimensions, and changes in dimensions. As compared with patients receiving placebo, patients receiving intravenous methylprednisolone had a somewhat shorter initial period of hospitalization (P=0.05) and, at week 1, a lower erythrocyte sedimentation rate (P=0.02) and a tendency toward a lower C-reactive protein level (P=0.07). However, the two groups had similar numbers of days spent in the hospital, numbers of days of fever, rates of retreatment with intravenous immune globulin, and numbers of adverse events.
Conclusions Our data do not provide support for the addition of a single pulsed dose of intravenous methylprednisolone to conventional intravenous immune globulin therapy for the routine primary treatment of children with Kawasaki disease. (ClinicalTrials.gov number, NCT00132080
[ClinicalTrials.gov]
.)
Source Information
From Children's Hospital and Harvard Medical School, Boston (J.W.N., A.L.B., S.D.C., R.P.S.); New England Research Institutes, Watertown, MA (L.A.S., P.D.M., G.L.K.); the University of Toronto, Hospital for Sick Children, Toronto (B.W.M.); Primary Children's Medical Center, Salt Lake City (L.L.M.); Columbia University Medical Center, New York (W.G.); Children's Hospital of Philadelphia, Philadelphia (V.L.V.); Medical University of South Carolina, Charleston (A.M.A.); Duke University Medical Center, Durham, NC (J.S.L.); and Children's Hospital of Los Angeles and University of Southern California, Los Angeles (M.T.).
Address reprint requests to Dr. Newburger at the Department of Cardiology, Children's Hospital, 300 Longwood Ave., Boston, MA 02115, or at jane.newburger{at}cardio.chboston.org.
Related Letters:
Treatment of Kawasaki Disease
Inoue Y., Kobayashi T., Morikawa A., Taddio A., Rosé C. D., Greil G. F., Manning W. J., Newburger J. W., Sleeper L. A., Burns J. C.
Extract |
Full Text |
PDF
N Engl J Med 2007;
356:2746-2748, Jun 28, 2007.
Correspondence
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |
Previous
